Compare First Solar, Inc. (FSLR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Globus Medical Inc. Class A Common Stock — how do they compare? First Solar, Inc. trades at $177.21 (market cap $20.05B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: First Solar, Inc. is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FSLR | GMED | |
|---|---|---|
Market Cap | $20.05B | $10.25B |
Volume | 2,420,017 | 1,108,124 |
Sector | Energy | Health |
52-Week High | $318.30 | $96.82 |
52-Week Low | $172.11 | $58.33 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $18.52B | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $179.08, down 0.36% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins exceeding 29%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed estimates. Analyst consensus remains positive with a $268.82 price target, while technical indicators show resistance near $181 with oversold RSI conditions.
FSLR presents a value opportunity with attractive valuation multiples (P/E 11.5, P/S 3.73) and strong profitability (ROE 18.51%). Risks include sector-wide pressure from high borrowing costs, patent litigation uncertainties, and recent insider selling. The stock's 35% decline from peaks creates potential upside if solar sector sentiment improves.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
